![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LPHN2 |
Gene summary for LPHN2 |
![]() |
Gene information | Species | Human | Gene symbol | LPHN2 | Gene ID | 23266 |
Gene name | adhesion G protein-coupled receptor L2 | |
Gene Alias | CIRL2 | |
Cytomap | 1p31.1 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | O95490 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23266 | LPHN2 | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 2.22e-03 | 5.34e-01 | 0.159 |
23266 | LPHN2 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 3.76e-15 | 5.71e-01 | 0.1633 |
23266 | LPHN2 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 4.57e-21 | 6.84e-01 | 0.1608 |
23266 | LPHN2 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 8.77e-19 | 7.58e-01 | 0.1604 |
23266 | LPHN2 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 4.44e-11 | 4.43e-01 | 0.1621 |
23266 | LPHN2 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 3.06e-05 | 4.84e-01 | 0.1619 |
23266 | LPHN2 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 1.73e-08 | 4.64e-01 | 0.1602 |
23266 | LPHN2 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 5.51e-03 | 3.17e-01 | 0.1608 |
23266 | LPHN2 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 1.14e-06 | 5.87e-01 | 0.1622 |
23266 | LPHN2 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 4.17e-05 | 2.58e-01 | 0.1575 |
23266 | LPHN2 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.66e-03 | 2.54e-01 | 0.1545 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Prostate | ![]() | BPH: Benign Prostatic Hyperplasia |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |